Literature DB >> 28339145

Respiratory syncytial virus-Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life.

Giovanni A Rossi1, Andrew A Colin2.   

Abstract

Respiratory syncytial virus (RSV) is the most common agent of severe airway disease in infants and young children. Large epidemiologic studies have demonstrated a clear relationship between RSV infection and subsequent recurrent wheezing and asthma into childhood, thought to be predominantly related to long-term changes in neuroimmune control of airway tone rather than to allergic sensitization. These changes appear to be governed by the severity of the first RSV infection in infancy which in term depends on viral characteristics and load, but perhaps as importantly, on the genetic susceptibility and on the constitutional characteristic of the host. A variety of viral and host factors and their interplay modify the efficiency of the response to infection, including viral replication and the magnitude of structural and functional damage to the respiratory structures, and ultimately the extent, severity, and duration of subsequent wheezing.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  adaptive immune response; asthma; bronchial hyperreactivity; bronchiolitis; nasopharyngeal aspirate; neurogenic inflammation; viral infections

Mesh:

Year:  2017        PMID: 28339145     DOI: 10.1111/pai.12716

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  11 in total

1.  Alternaria alternata challenge at the nasal mucosa results in eosinophilic inflammation and increased susceptibility to influenza virus infection.

Authors:  M Ma; J L Redes; C M Percopo; K M Druey; H F Rosenberg
Journal:  Clin Exp Allergy       Date:  2018-04-15       Impact factor: 5.018

2.  Role of viral coinfections in asthma development.

Authors:  Maria Luz Garcia-Garcia; Cristina Calvo; Sara Ruiz; Francisco Pozo; Victoria Del Pozo; Laura Remedios; Nadia Exposito; Ana Tellez; Inmaculada Casas
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

Review 3.  Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus.

Authors:  Karen Bohmwald; Janyra A Espinoza; Raúl A Pulgar; Evelyn L Jara; Alexis M Kalergis
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

Review 4.  Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Authors:  Bernhard Resch
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

5.  Association of Serum Albumin With Apnea in Infants With Bronchiolitis: A Secondary Analysis of Data From the MARC-35 Study.

Authors:  Jonathan M Mansbach; Ruth J Geller; Kohei Hasegawa; Janice A Espinola; Michelle D Stevenson; Ashley F Sullivan; Carlos A Camargo
Journal:  JAMA Netw Open       Date:  2019-07-03

6.  Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.

Authors:  Renato Cutrera; Andrea Wolfler; Simonetta Picone; Giovanni A Rossi; Giuliana Gualberti; Rocco Merolla; Antonio Del Vecchio; Alberto Villani; Fabio Midulla; Andrea Dotta
Journal:  Ital J Pediatr       Date:  2019-11-09       Impact factor: 2.638

Review 7.  Early-Life Lung and Gut Microbiota Development and Respiratory Syncytial Virus Infection.

Authors:  Kazuma Yagi; Nobuhiro Asai; Gary B Huffnagle; Nicholas W Lukacs; Wendy Fonseca
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

Review 8.  Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?

Authors:  Giovanni A Rossi; Oliviero Sacco; Antonino Capizzi; Paola Mastromarino
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.

Authors:  Dirk Roymans; Sarhad S Alnajjar; Michael B Battles; Panchan Sitthicharoenchai; Polina Furmanova-Hollenstein; Peter Rigaux; Joke Van den Berg; Leen Kwanten; Marcia Van Ginderen; Nick Verheyen; Luc Vranckx; Steffen Jaensch; Eric Arnoult; Richard Voorzaat; Jack M Gallup; Alejandro Larios-Mora; Marjolein Crabbe; Dymphy Huntjens; Pierre Raboisson; Johannes P Langedijk; Mark R Ackermann; Jason S McLellan; Sandrine Vendeville; Anil Koul
Journal:  Nat Commun       Date:  2017-08-01       Impact factor: 14.919

Review 10.  The Virome and Its Major Component, Anellovirus, a Convoluted System Molding Human Immune Defenses and Possibly Affecting the Development of Asthma and Respiratory Diseases in Childhood.

Authors:  Giulia Freer; Fabrizio Maggi; Massimo Pifferi; Maria E Di Cicco; Diego G Peroni; Mauro Pistello
Journal:  Front Microbiol       Date:  2018-04-10       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.